Key result
Serum ANGPTL2 levels significantly discriminated patients with gastric cancer from healthy individuals with an area under the ROC curve of 0.774.
Why the study?
Does serum ANGPTL2 level accurately discriminate patients with gastric cancer from healthy individuals?
Population
50 human participants from Japan, and human gastric cancer cell lines.
Comparison
Measurement of serum angiopoietin-like protein 2… vs Healthy controls and differentiated MKN7 cells.
Design
Case-control
Authors
Loading...
Supports ANGPTL2 as gastric cancer biomarker; hypothesis-generating in case-control data and requires prospective validation.
Case-Control (n=50)
No
Does serum ANGPTL2 level accurately discriminate patients with gastric cancer from healthy individuals?
Effect estimate: AUC 0.774 (95% CI 0.615-0.933)
p-value: p=0.005
ANGPTL2 is upregulated in undifferentiated gastric cancer cells and patients, suggesting it is a potential clinically relevant biomarker for gastric cancer.
Yoshinaga et al. (2014) conducted a case-control in Gastric cancer (n=50). Serum ANGPTL2 levels vs. Healthy controls was evaluated on Discrimination of patients with gastric cancer from healthy individuals (Area Under the ROC Curve) (AUC 0.774, 95% CI 0.615-0.933, p=0.005). Serum ANGPTL2 levels significantly discriminated patients with gastric cancer from healthy individuals with an area under the ROC curve of 0.774.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: